Entera Bio

ENTX Rare disease Lead: Phase 2 1 Biotech Distilled article ↓

Most recent annual filing: 2026-03-27

Catalyst timeline

EB618 IND filing2026EB618 IND filing, 2026, notable
EB613 Ph3 startLate 2026EB613 Ph3 start, Late 2026, routine
EB612 IND filing1H 2027EB612 IND filing, 1H 2027, notable
EB613 / pipeline enrollment done2027EB613 / pipeline enrollment done, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

oral teriparatide

teriparatide · EB613

Peptide Target: PTH(1-34)

Osteoporosis Phase 2 oral NCT02202603

oral PTH(1-34)

EB612

Peptide Target: PTH(1-34)

Hypoparathyroidism Phase 1 oral OPKO Health NCT03516773

oral oxyntomodulin

oral OXM · EB618 · OPK-88006

Peptide Target: GLP-1, Glucagon

Obesity Preclinical oral OPKO Health

oral GLP-2

OPK-8801003

Peptide Target: GLP-2

Short Bowel Syndrome Preclinical oral OPKO Health

Technology platforms

N-Tab

Oral peptide and protein delivery platform designed to simultaneously stabilize large (4kD+) hydrophilic peptides in the gastrointestinal tract and promote their absorption into the bloodstream; applied to osteoporosis, hypoparathyroidism, obesity/metabolic disorders, and short bowel syndrome

Biotech Distilled coverage (1)

2026-07-30 Entera Bio (ENTX) — Scientific Deep Dive for EB613 and the N-Tab® Oral Peptide Pipeline 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.